Company intelligence
Crown Bioscience
Our mission is to empower our customers to improve human health.
About Crown Bioscience
Crown Bioscience is a global contract research organization (CRO) dedicated to accelerating drug discovery and development in oncology and immuno-oncology. We partner with biotech and pharmaceutical companies to deliver integrated preclinical and translational research solutions, supporting programs from target discovery through clinical development. Our portfolio includes more than 2,800 patient-derived xenograft (PDX) models and approximately 1,000 tumor organoid models across 35 cancer indications, supported by expertise in in vivo, in vitro, ex vivo, and in silico research. Combined with advanced laboratory services, multiomics capabilities, and data science, we help generate the insights needed to support confident decision-making throughout the drug development continuum. Operating from 9 facilities across the US, Europe, and APAC, our laboratories meet the highest industry standards and include CAP-, CLIA-, and ISO 15189-accredited facilities. To learn more, visit www.crownbio.com
Verified activity
Signals from Crown Bioscience
5 published signals
Presence & Recognition
Crown Bioscience is hosting a webinar to register and discuss upcoming details.
Reported by Jonathan Seager
Research & Knowledge
Crown Bioscience conducted a multi-omic comparison of preclinical cancer models, integrating transcriptomic, proteomic, and genomic data from over 10,000 primary tumors and nearly 4,000 preclinical models.
Reported by Crown Bioscience
Presence & Recognition
Crown Bioscience researchers and drug discovery leaders are attending the Museum of Science, Boston on September 16 for an afternoon of cutting-edge science, meaningful connections, and translational research insights.
Reported by Crown Bioscience
Presence & Recognition
Crown Bioscience is hosting an upcoming webinar exploring how to integrate in vitro stability, in vivo PK/PD, humanized models, toxicology, and bioanalysis to build a clearer translational picture and support more accurate human dose projections.
Reported by Crown Bioscience
Research & Knowledge
Crown Bioscience published recent data from models showcasing distinct approaches to therapeutic resistance in lung cancer, including engineering patient-derived organoids with TROP2 knockout and evaluating resistance in pretreated NSCLC PDX and organoid systems.
Reported by Crown Bioscience